突触蛋白组补偿与阿尔茨海默病精神病性症状的抗性
该研究探讨阿尔茨海默病(AD)中精神病性症状抗性的神经生物学基础,通过定量免疫组化和液相色谱-质谱法比较有无精神病性症状的AD患者及未受累对照的突触蛋白水平,并在APPswe/PSEN1dE9小鼠模型中验证Kalrn减少的影响。结果显示,对精神病性症状有抗性的AD患者突触蛋白水平更高,神经病理负荷预测精神病性状态方差不足20%且不能解释组间突触蛋白差异;小鼠中Kalrn减少导致皮层匀浆突触蛋白升高并使突触后密度蛋白水平正常化。结论认为突触蛋白尤其是突触后密度富集蛋白的积累与AD精神病性症状抗性相关。
要点
- AD精神病性症状抗性者突触蛋白水平高于有精神病性症状者和未受累对照。
- 神经病理负荷预测精神病性状态方差不足20%,不解释突触蛋白差异。
- Kalrn减少使AD小鼠模型皮层匀浆突触蛋白升高并正常化突触后密度蛋白。
核心结论
- 突触蛋白尤其是突触后密度富集蛋白的积累与阿尔茨海默病中对精神病性症状的抗性相关。
- 突触蛋白组补偿的候选机制是促进突触蛋白往返突触后密度的蛋白质水平改变。
研究设计与样本
- 研究采用定量免疫组化测量早中期阿尔茨海默病患者背外侧前额叶皮层的多种神经病理,并通过液相色谱-质谱法量化灰质匀浆中的突触蛋白。
- 研究还在APPswe/PSEN1dE9小鼠模型(伴Kalrn种系减少)的皮层灰质匀浆和突触后密度组分中评估突触蛋白组。
主要发现
- 对精神病性症状有抗性的阿尔茨海默病患者突触蛋白水平高于有精神病性症状者和未受累对照。
- 神经病理负荷预测精神病性状态方差不足20%,且不能解释组间突触蛋白水平差异。
- APPswe/PSEN1dE9小鼠中Kalrn减少导致皮层匀浆突触蛋白水平升高并使突触后密度蛋白水平正常化。
关键数值与推荐
- 神经病理负荷预测精神病性状态方差不足20%。
- 对精神病性症状有抗性的阿尔茨海默病患者突触蛋白水平高于有精神病性症状者和未受累对照。
- Kalrn减少的APPswe/PSEN1dE9小鼠皮层匀浆突触蛋白水平升高且突触后密度蛋白水平正常化。
临床怎么用
- 突触蛋白组尤其是突触后密度富集蛋白可能作为阿尔茨海默病精神病性症状抗性的生物标志物或治疗靶点。
- 促进突触蛋白往返突触后密度的机制可能为预防或治疗阿尔茨海默病精神病性症状提供新方向。
局限性
- 研究未明确报告样本量、置信区间或P值等统计细节。
- 小鼠模型结果需进一步在人类中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The presence of psychosis in Alzheimer's disease denotes a phenotype with more rapid cognitive deterioration than in Alzheimer's disease without psychosis. Discovery of novel pharmacotherapies that engage therapeutic targets for prevention or treatment of Alzheimer's disease with psychosis would benefit from identifying the neurobiology of resilience to psychosis in Alzheimer's disease. The primary objective of this study was to determine whether alterations in the synaptic proteome were associated with resilience to psychotic symptoms in Alzheimer's disease and, if present, were independent of neuropathologic burden. METHOD: Quantitative immunohistochemistry was used to measure multiple neuropathologies in dorsolateral prefrontal cortex from subjects with early and middle-stage Alzheimer's disease who differed in psychosis status. Synaptic proteins were quantified by liquid chromatography-mass spectrometry in gray matter homogenates from these subjects and from neuropathologically unaffected subjects. The synaptic proteome was similarly evaluated in cortical gray matter homogenate and in postsynaptic density fractions from an APPswe/PSEN1dE9 mouse model of amyloidosis with germline reduction in Kalrn, which has been shown to confer resilience to progression of psychosis-associated behaviors relative to APPswe/PSEN1dE9 alone. RESULTS: Subjects resilient to psychotic symptoms in Alzheimer's disease had higher levels of synaptic proteins compared with those with psychosis and unaffected control subjects. Neuropathologic burden predicted less than 20% of the variance in psychosis status and did not account for the synaptic protein level differences between groups. Reduction of Kalrn in APPswe/PSEN1dE9 mice resulted in higher levels of synaptic proteins in cortical homogenate and normalized protein levels in the postsynaptic density. CONCLUSIONS: Accumulation of synaptic proteins, particularly those that are enriched in the postsynaptic density, is associated with resilience to psychosis in Alzheimer's disease. One candidate mechanism for this synaptic proteome compensation is alteration in levels of proteins that facilitate the transport of synaptic proteins to and from the postsynaptic density.
引用
- Krivinko JM, Erickson SL, Ding Y, et al. Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry. 2018. PMID: 30021459. doi:10.1176/appi.ajp.2018.17080858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。